TREATMENT OF MULTIPLE MYELOMA WITH RECOMBINANT \( \alpha \)-INTERFERON

By Jorge R. Quesada, Raymond Alexanian, Michael Hawkins, Barthel Barlogie, Ernest Borden, Loretta Itri, and Jordan U. Gutterman

Thirty-two patients with multiple myeloma were treated with recombinant \( \alpha \)-interferon clone A (rifNaA) daily by intramuscular injection with an initial dose of \( 12 \times 10^8 \) U/m\(^2\). Of 27 patients evaluable for response, tumor responses were obtained in seven of 14 previously untreated patients (50%) and two of 13 who had relapsed or failed prior chemotherapy (15%). In all patients who had tumor response, there was restoration from subnormal levels of serum immunoglobulins, an effect infrequently observed with chemotherapy. The median duration of tumor responses exceeded 14 months (range, 6 to 20). Moderate-to-severe fatigue was the predominant side effect and necessitated dose reductions in all patients. We conclude that treatment of early stages of multiple myeloma with rifNaA is beneficial because of the substantial response rate and the improvement in the synthesis of serum immunoglobulins. rifNaA has a potential role in combination with other agents in the treatment of multiple myeloma.

EARLY CLINICAL STUDIES of partially purified \( \alpha \)-interferon (IFNa) reported antitumor activity in patients with multiple myeloma.\(^1,2\) Subsequent studies have confirmed the activity of both partially purified and cloned IFNa in a limited number of patients.\(^3,4\) In this study we have examined the activity of high doses of recombinant DNA–derived \( \alpha \)-interferon (rifNaA) in patients with multiple myeloma, including both previously untreated patients and those whose disease was refractory to prior chemotherapy.

A high response rate was found among previously untreated patients but limited activity in patients with refractory myeloma. In addition, we present evidence that rifNaA restored subnormal levels of serum immunoglobulins to normal levels in all responsive patients, an effect not frequently observed in patients responding to chemotherapy.

MATERIALS AND METHODS

Patient population and study design. Thirty-two patients were entered in the study. Criteria for a diagnosis of multiple myeloma included a monoclonal immunoglobulin in serum or monoclonal light chains in urine (or both) and at least one of the following: atypical bone marrow plasmacytosis of 15% or more, osteolytic lesions on x-ray examinations related only to the increased plasma cells, or bone biopsy results revealing plasma cell proliferation. Eligibility criteria included a performance status of \( \leq 60 \) (Karnofsky scale), an expected survival of \( \geq 12 \) weeks, preserved renal (creatinine level of \( \leq 2.0 \) mg/dL) and liver function, granulocyte count above \( 1,500/\mu L \), and a platelet count above \( 100,000/\mu L \). In all previously treated patients, we required that there were at least 4 weeks between the last treatment and the onset of interferon therapy.

All patients had a clinical examination and staging of their disease before initiation of rifNaA treatment. Tests performed within 1 week of the first injection included complete blood cell counts, differential count, platelet and reticulocyte counts, 12-channel blood chemistry, coagulation parameters, urinalysis, electrocardiogram, chest x-ray, serum and urine protein electrophoresis, bone marrow examinations, and bone surveys. Serum immunoglobulins were determined by quantitative nephelometry and Bence Jones proteinuria. Response in one patient with nonsecretory multiple myeloma was confirmed when previously marked plasma cell infiltrates disappeared on multiple bone marrow specimens. Serum immunoglobulin response was defined as an increase in IgM of \( \geq 40 \) mg/100 mL to the normal value (\( \leq 30 \) mg/100 mL), an increase in IgA of \( \geq 60 \) mg/100 mL to the normal value (\( \leq 20 \) mg/100 mL), and an increase in IgG of \( \geq 400 \) mg/100 mL to the normal value (\( \leq 650 \) mg/100 mL).

RESULTS

Table 1 summarizes the characteristics of the study population, which included 26 patients at the University of Texas M.D. Anderson Hospital and six at Wisconsin Clinical Cancer Center. The extent of tumor mass was low or intermediate in all but four of the previously treated patients. Of the 15 previously untreated patients, eight were asymptomatic, and seven had symptoms referable to lytic lesions.

From the Departments of Clinical Immunology and Biological Therapy and the Department of Hematology, The University of Texas M.D. Anderson Hospital and Tumor Institute at Houston; the Division of Human Oncology and Medicine, Wisconsin Clinical Cancer Center, Madison; and Hoffmann LaRoche, Inc, Nutley, N.J.

Supported by a grant from Hoffmann LaRoche, Inc. Research conducted in part by the Clayton Foundation for Research and the James E. Lyon Medical Research Foundation.

Dr Gutterman is a Senior Clayton Foundation investigator. Dr Hawkins is now affiliated with the Cancer Therapy and Evaluation Program, National Cancer Institute, Bethesda, MD.


Address reprint requests to Dr Jorge R. Quesada, Department of Clinical Immunology and Biological Therapy, The University of Texas M.D. Anderson Hospital and Tumor Institute at Houston, 6723 Bertner Ave, Houston, TX 77030.

© 1986 by Grune & Stratton, Inc.
0006-4971/86/6702-0004$03.00/0
None of these 15 had hypoalbuminemia, hypercalcemia, or azotemia, but three had a hemoglobin value of <10 g/dL. Thus, most met the criteria for indolent myeloma. All previously treated patients had received combination chemotherapy with intermittent courses of melphalan and prednisone or combinations of alkylating agents and doxorubicin. Four patients were treated upon relapse from prior successful therapy. The remaining patients had disease refractory to preceding combinations of chemotherapy.

**Tumor responses.** Twenty-seven patients were evaluable for tumor response. Five were not evaluable because they received treatment for less than 2 weeks because of evidence of excessive toxicity. Table 2 shows the results of treatment. Tumor responses were obtained in seven of 14 previously untreated patients (50%), whereas only two of 13 patients responded after failing prior chemotherapy (15%). Among the nine who had responses, seven had a low-tumor mass, and two had an intermediate-tumor mass; five had IgG myeloma protein, three had IgA myeloma protein, and one had a nonsecretory myeloma. Tumor responses occurred within 1 to 4 months (median, 2 months) and lasted from 6 to 20+ months (median, 14+ months). Three previously untreated patients maintained tumor remission beyond 12 months without further interferon therapy. Five of seven previously untreated patients who did not respond to rIFNa achieved tumor responses with subsequent chemotherapy.

**Immunoglobulin response.** Restoration of depressed levels of one or two of the normal serum immunoglobulins was observed in all patients who had tumor responses (Fig 1). The time needed to achieve normal immunoglobulin levels in these patients ranged from 3 to 10 months (median, 4.5 months). Restoration was observed in six of six patients with subnormal IgA levels, in seven of nine with subnormal IgM, and in four of four with subnormal IgG. Figure 2 depicts the pattern of immunoglobulin response in one patient. Concurrent with the reduction of the myeloma protein in this patient, recovery of serum IgA and IgM was first observed after 3 months, with normal levels achieved after 6 months of treatment. In contrast, none of the patients who did not have a tumor response showed a detectable increase in serum immunoglobulins.

**Toxicity.** All patients were evaluable for toxicity, which was similar to that described in cancer patients receiving daily administration of rIFNa. Fatigue and asthenia were the most common symptoms and accounted for most treatment interruptions, dose reductions, or drug discontinuations. A 50% dose reduction was indicated within 8 weeks of initiation of treatment in 20 patients (62%) and within 24 weeks in the remaining 12.

Hematologic toxicity included decrements of hemoglobin of 1 to 3 g/dL (median, 1.8 g/dL) within 4 to 12 weeks of treatment in 23 patients (72%). Transient severe granulocytopenia (≤1,500 cells per μL) occurred in five patients (16%). A mild and slow decrease in platelet counts (between 50 and 100,000/μL) was observed in eight patients (25%), in keeping with prior observations. However, rapid onset of thrombocytopenia (within 2 weeks counts below 50,000 cells per μL) consistent with an autoimmune phenomenon but reversible with discontinuation of rIFNaA developed in four other patients. These four patients, as well as one other with high-tumor mass who developed acute tubular necrosis after three doses of rIFNaA, received treatment for less than 2 weeks and were considered to be ineligible for tumor response. Lastly, mild elevations of serum glutamic oxalo-
DISCUSSION

This study confirmed the therapeutic activity of rIFNaA in patients with multiple myeloma; such activity has been previously noted with partially purified IFNα interferon. We used a highly purified, single-molecular species of IFNα, which has also been effective in inducing remission of other B cell malignancies, including low-grade lymphomas and hairy cell leukemia. The 50% response rate among our untreated patients is superior to the 14% response rate recently reported in a study that used partially purified IFNα at lower doses (3 × 10⁷ U/d).⁴

The greater activity in our study may be related to the type of interferon, the higher dose, or our selection of patients with early disease. A dose response effect to rIFNaA has been suggested in patients with Kaposi's sarcoma or renal cell carcinoma. However, that the present response rate in refractory myeloma is not better than that of other studies and that a higher response rate can be obtained in low–tumor mass myeloma with chemotherapy suggests that patient selection played a predominant role in our results.

Noteworthy is the disparity in the responsiveness among several B cell lymphoid malignancies to IFNα, from the relative resistance of intermediate- and high-grade lymphomas or advanced chronic lymphocytic leukemia, to moderate sensitivity of low-grade lymphomas and multiple myeloma, and to high susceptibility in hairy cell leukemia. There is present no information that may relate these different levels of sensitivity with the stage of differentiation or the expression of cellular receptors in the malignant cells. Of interest, however, is the recent finding of plasma cell–associated antigens on hairy cells that provides a phenotypic link between these two IFNα-sensitive tumors.

The recovery of normal levels of serum immunoglobulins in all patients with tumor response contrasts with a similar recovery in only 25% of comparable patients responding to chemotherapy. The deficiency in immunoglobulin synthesis was induced by a plasma cell-derived activating factor. In this regard, both IFNα and highly purified rIFNaA stimulate immunoglobulin production in vitro. Such stimulation was dependent on the presence of T helper cells and seemed to be related to the ability of IFNα to enhance the response of B cells to T helper–derived soluble factors.

We conclude that further studies of rIFNaA in patients with early stages of multiple myeloma are justified because of an adequate response rate associated with restoration of synthesis of serum immunoglobulins; further, rIFNaA does not preclude a later tumor response to chemotherapy. In fact, the tolerance to subsequent chemotherapy may be improved by reduction of the risk of infections in patients with a restored humoral immune response. The rIFNaA had acceptable toxicity at an average daily dose of 6 × 10⁶ U/m². It is unknown whether lower and perhaps less toxic doses might achieve comparable results.

The low response rate in patients previously treated with chemotherapy was similar to our previous observations on rIFNaA in refractory multiple myeloma. However, our findings offer promise for further developments with rIFNaA as part of combination therapies. In this regard, in vitro synergism of IFNα with either γ-interferon, difluoromethylornithine, double-stranded RNA, or some chemotherapeutic agents has already been demonstrated. Further, in view of the antitumor activity of high doses of glucocorticoids in refractory myeloma, clinical studies combining steroids and rIFNaA are of interest, both because of potential enhancement of the therapeutic activity of either agent and because of possible improvement in the tolerance to high doses of IFNα.

ACKNOWLEDGMENT

The authors wish to acknowledge the assistance of the nursing staff: Andrea Linder, Donnah Jones, Paula DeAvies, Margaret Harle, Sue Schmidt (M.D. Anderson Hospital and Tumor Institute), and Jill Aughey (Wisconsin Clinical Cancer Center). They also express their gratitude to John Kolsbun, a physician assistant; data managers Marion Stringer, Elaine Stehr, Sandra Iceth, and Brigetta Burgess; and to Linda Reckeweg for her impeccable secretarial assistance.

REFERENCES

7. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with present-
ing clinical features, response to treatment and survival. Cancer 36:842, 1975
Treatment of multiple myeloma with recombinant alpha-interferon

JR Quesada, R Alexanian, M Hawkins, B Barlogie, E Borden, L Itri and JU Gutterman